Quest diagnostics and ultima collaborate to scale ultima's technology in fast-growing minimal residual disease and whole genome sequencing

Fremont, calif & secaucus, n.j.--(business wire)--ultima genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and quest diagnostics (nyse: dgx), the nation's leading provider of diagnostic information services, today announced a collaboration involving ultima's next generation sequencing (ngs) technology in oncology and other clinical areas. the collaboration aims to improve patient access, affordability and outcomes by broadening the use of highly accurat.
DGX Ratings Summary
DGX Quant Ranking